To investigate the involvement of proteases in apoptosis, rat thymocyt
es were treated with the glucocorticoid hormone methylprednisolone or
the topoisomerase II inhibitor etoposide in the presence of selective
substrate inhibitors of either interleukin-1 beta-converting enzyme (I
CE), (Z-Val-Ala-Asp-chloromethylketone, VADcmk) or Ca2+-regulated seri
ne protease (Suc-Ala-Ala-Pro-Phe-chloromethylketone, AAPFcmk), VADcmk
protected from lamin proteolysis, chromatin fragmentation, cell shrink
age, and formation of apoptotic nuclei in both methylprednisolone-and
etoposide-treated thymocytes when present during the initiation of the
apoptotic process, AAPFcmk prevented lamin breakdown, chromatin fragm
entation, and apoptotic morphological changes in thymocytes treated wi
th methylprednisolone, but not with etoposide. Both MPS- and etoposide
-treated thymocytes exhibited enhanced ICE-like protease activity whic
h was maximal 1 h after treatment, This increase in proteolytic activi
ty was blocked by VADcmk, but not AAPFcmk, Our findings suggest that I
CE-like protease activity is critically involved in the early phase of
both methylprednisolone- and etoposide-induced apoptosis in thymocyte
, whereas the Ca2+-regulated serine protease is an obligatory componen
t of the proteolytic cascade in methylprednisolone-induced apoptosis.
(C) 1995 Academic Press, Inc.